European Archives - Page 910 of 963 - European Medical Journal

EMJ

The importance of the St. Gallen Breast Cancer Conference

Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International Breast Cancer…

A New Approach for the Patient with Erectile Dysfunction

This satellite symposium was held in two sessions. The first session was offered in a traditional format where invited experts reviewed and discussed the…

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points

The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant…

Pushing the Limits with Nanoknife®: A Promising New Technology in Localised Prostate Cancer Management

In the last few decades, the ever-increasing improvements in cancer detection have allowed urologists to detect prostate cancer (PrC) at earlier stages…

Chemotherapy and New Drugs in Prostate Cancer

Prostate cancer (PrC) is the fourth most common cancer (for both sexes combined) and the second most common cancer in men (accounting for 15% of all new…

Holmium Laser Enucleation of the Prostate (HoLEP): Our Experience with the Learning Curve and the Development of the ‘En-Bloc No-Touch’ Technique

Background: Holmium laser enucleation of the prostate (HoLEP) is a safe and effective therapeuticoption in patients suffering from benign prostatic…

Holmium Laser Enucleation of the Prostate (HoLEP) in Ambulatory Surgery

The focus of this work is the need to give an update on the holmium laser enucleation of the prostate (HoLEP) technique in ambulatory surgery.

Evolving Techniques for Surgical Treatment of Benign Prostatic Hyperplasia

The management of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is one of the most topical areas in urology. Although most…

EMJ Urology 3.2 2015

Hello and welcome to the second edition of European Medical Journal Urology, our publication devoted to covering recent developments in all of the…

EMJ

The Scottish Medicines Consortium Approves Gilead’s Zydelig® q (Idelalisib) for the Treatment of Follicular Lymphoma That Is Refractory to Two Prior Lines of Treatment in Adult Patients

Foster City, CA, 11 May 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Scottish Medicines Consortium (SMC) has approved Zydelig…